StevenSchusterSteven R Schuster39.74389450000000-104.8394352000000013675Schuster, StevenR970/493-6337Asst Professor-Clinicalprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDanielSherbenou9OkOZriw1xnZPhg0fmXYl1FGSoYfD0+wHFBWvvLDHw==Daniel W Sherbenou39.74273230000000-104.8391914000000010241Sherbenou, DanielAssociate Professor5Other Faculty1Professor3Asst Professor2Assoc Professor4InstructorAmandaWintersAmanda Catherine Winters39.74403510000000-104.8360594000000013003Winters, AmandaAsst ProfessorHeatherLeachHeather Jean Leach39.74701990000000-104.8439827000000013052Leach, HeatherAffiliate12801 E 17th Ave2RC1SResearch South Tower12801 E 17th AveAurora80045-2570CO0.8831910.0043390293research areas0.7033930.04596715coauthor of8.20881.8866360similar to1112selected publicationsAuthorship 17298813Authorship 1730551Authorship 1731991Authorship 1735663Authorship 1739802Authorship 1740351Authorship 1743392Authorship 174426120842638Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R, Mikhael JAmerican journal of hematologySchuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R, Mikhael J. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol. 2010 Nov; 85(11):853-5.Am J Hematol2010-11-01T00:00:002010IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.25562201Schuster SR, Pockaj BA, Bothe MR, David PS, Northfelt DWJournal of personalized medicineSchuster SR, Pockaj BA, Bothe MR, David PS, Northfelt DW. Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: a case report. J Pers Med. 2012 Sep 10; 2(3):71-6.J Pers Med2012-09-10T00:00:002012Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: a case report.22180256Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy ACancerMato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012 Jul 15; 118(14):3565-70.Cancer2011-12-16T00:00:002011Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.24565465Kortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AKClinical lymphoma, myeloma & leukemiaKortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AK. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):284-290.e5.Clin Lymphoma Myeloma Leuk2013-12-28T00:00:002013Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.22331188Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca RBloodMikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10; 119(19):4391-4.Blood2012-02-13T00:00:002012Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.24129344Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AKLeukemia researchSchuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014 Jan; 38(1):23-8.Leuk Res2013-09-05T00:00:002013The clinical significance of cereblon expression in multiple myeloma.17679802Schuster SR, Tabba M, Sahota PJournal of the cardiometabolic syndromeSchuster SR, Tabba M, Sahota P. Relationship between the cardiometabolic syndrome and obstructive sleep apnea. J Cardiometab Syndr. 2006; 1(3):204-8.J Cardiometab Syndr2006-01-01T00:00:002006Relationship between the cardiometabolic syndrome and obstructive sleep apnea.23076627Cherington C, Schuster SR, Kundranda M, Valdez R, Mesa RA, Northfelt DWAmerican journal of hematologyCherington C, Schuster SR, Kundranda M, Valdez R, Mesa RA, Northfelt DW. A surprising cause of masses in the chest. Am J Hematol. 2013 Jun; 88(6):518-21.Am J Hematol2012-10-17T00:00:002012A surprising cause of masses in the chest.D009101Disorders471030.884309Multiple MyelomaD000971Procedures33314020.548184Antineoplastic Combined Chemotherapy ProtocolsD005081Procedures1643750.724312Exercise TherapyErynCallihanEryn Brook Sullivan Callihan39.74389450000000-104.8394352000000014617Callihan, ErynInstructorAuthorship 197091630767964Leach HJ, Covington KR, Voss C, LeBreton KA, Harden SM, Schuster SROncology nursing forumLeach HJ, Covington KR, Voss C, LeBreton KA, Harden SM, Schuster SR. Effect of Group Dynamics-Based Exercise Versus Personal Training in Breast Cancer Survivors. Oncol Nurs Forum. 2019 03 01; 46(2):185-197.Oncol Nurs Forum2019-03-01T00:00:002019Effect of Group Dynamics-Based Exercise Versus Personal Training in Breast Cancer Survivors.MaryHiddeMary C Hidde39.74389450000000-104.8394352000000015347Hidde, MaryAffiliateD000073116892250.71107Cancer SurvivorsD011615Procedures53680.931912Psychotherapy, GroupONC GENERAL OPERATIONSSOM-MEDSOM-PEDSHematologyOncBoneMarrow TransplantUniversity of Colorado Denver - Anschutz Medical CampusLih-JenSuLih-Jen S Su39.74389450000000-104.839435200000001010Su, Lih-JenResearch Senior InstructorElaineLamElaine Tat Lam39.74273230000000-104.839191400000001894Lam, ElaineProfessorThomasFlaigThomas William Flaig39.74389450000000-104.839435200000001920Flaig, ThomasProfessorJohnArcaroliJohn J Arcaroli39.74389450000000-104.83943520000000235Arcaroli, JohnAsst Professor AdjunctDavidCamidgeDavid Ross Camidge39.74273230000000-104.839191400000002375Camidge, DavidProfessorDanielPollyeaDaniel Aaron Pollyea39.74273230000000-104.839191400000004039Pollyea, DanielProfessorVirginiaBorgesVirginia F. Borges39.74389450000000-104.839435200000001874Borges, VirginiaProfessorAuthorship 2106891631648312Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DABlood advancesWinters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 10 22; 3(20):2911-2919.Blood Adv2019-10-22T00:00:002019Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.ElizabethKesslerElizabeth Riley Kessler39.74273230000000-104.839191400000007797Kessler, ElizabethAssociate ProfessorAuthorship 2389401116269610Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CHBloodPorter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006 Feb 15; 107(4):1325-31.Blood2005-11-03T00:00:002005A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.Authorship 2838261037377613Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ETCancer research communicationsKessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.Cancer Res Commun2023-06-08T00:00:002023A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Asst ProfessorAsst Professortrue1Asst Professor AdjunctAsst Professor Adjuncttrue1Research Senior InstructorResearch Senior Instructortrue1ProfessorProfessortrue1InstructorInstructortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Asst Professor-ClinicalAsst Professor-Clinicaltrue1AffiliateAffiliatetrue1AffiliateAffiliate